Testing effectiveness (Phase 2)Looking for participantsNCT06789913
What this trial is testing
Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+4 more
Relay Therapeutics, Inc. 277